$NVO

Fave Five (11/18/2016)

expectingalpha Stocks , , , , , ,

Fave Five (11/18/2016)

Our Fave Five essentially represents a listing of stocks with favorable short term total return forecasts (1 year, according to Analyst Consensus Estimates, or ACE) combined with strong long-term return forecasts and good/excellent quality rankings.

This week, we seek the companies with the best return forecasts, highest quality and in a tribute to www.morningstar.com — the companies with the lowest price-to-fair value ratios as being potentially “on sale.” Context: A P/FV = 100% would indicate that a stock is priced at its fair value according to Morningstar.

The Fave Five This Week

  • Cognizant Technology (CTSH)
  • CVS Health (CVS)
  • Novo Nordisk (NVO)
  • Stericycle (SRCL)
  • Synaptics (SYNA)

The Long and Short of This Week’s Fave Five

The Long & Short. (November 18, 2016) Projected Annual Return (PAR): Long term return forecast based on fundamental analysis and five year time horizon. Quality Ranking: Percentile ranking of composite that includes financial strength, earnings stability and relative growth & profitability. VL Low Total Return (VLLTR): Low total return forecast based on 3-5 year price targets via Value Line Investment Survey. Morningstar P/FV: Ratio of current price to fundamentally-based fair value via www.morningstar.com S&P P/FV: Current price-to-fair value ratio via Standard & Poor’s. 1-Year ACE Outlook: Total return forecast based on analyst consensus estimates for 1-year target price combined with current yield. The data is ranked (descending order) based on this criterion. 1-Year S&P Outlook: 1-year total return forecast based on S&P 1-year price target. 1-Yr GS: 1-year total return forecast based on most recent price target issued by Goldman Sachs.

Weekend Warriors

The relative/excess return for the Weekend Warrior tracking portfolio is +5.0% since inception. 50.7% of selections have outperformed the Wilshire 5000 since original selection.

Tracking Dashboard: https://www.manifestinvesting.com/dashboards/public/weekend-warriors

Fave Five (10/21/2016)

expectingalpha Stocks , , , , , ,

Fave Five (10/21/2016)

Our Fave Five essentially represents a listing of stocks with favorable short term total return forecasts (1 year, according to Analyst Consensus Estimates, or ACE) combined with strong long-term return forecasts and good/excellent quality rankings.

So you’re looking at the stocks in the top 1% of all companies according to MANIFEST Rank (Return Forecast and Quality combination) that have the highest 1-year total return forecasts according to the analyst consensus estimates. (ACE)

The Fave Five This Week

  • Air Lease (AL)
  • Celgene (CELG)
  • Cognizant Technology (CTSH)
  • Novo Nordisk (NVO)
  • Universal Display (OLED)

Context: The median 1-year return forecast (ACE) is 10.6%.

The Long and Short of This Week’s Fave Five

The Long & Short. (October 21, 2016) Projected Annual Return (PAR): Long term return forecast based on fundamental analysis and five year time horizon. Quality Ranking: Percentile ranking of composite that includes financial strength, earnings stability and relative growth & profitability. VL Low Total Return (VLLTR): Low total return forecast based on 3-5 year price targets via Value Line Investment Survey. Morningstar P/FV: Ratio of current price to fundamentally-based fair value via www.morningstar.com S&P P/FV: Current price-to-fair value ratio via Standard & Poor’s. 1-Year ACE Outlook: Total return forecast based on analyst consensus estimates for 1-year target price combined with current yield. The data is ranked (descending order) based on this criterion. 1-Year S&P Outlook: 1-year total return forecast based on S&P 1-year price target. 1-Yr GS: 1-year total return forecast based on most recent price target issued by Goldman Sachs.

Weekend Warriors

The relative/excess return for the Weekend Warrior tracking portfolio is +12.9% since inception. 42.6% of selections have outperformed the Wilshire 5000 since original selection.

Tracking Dashboard: https://www.manifestinvesting.com/dashboards/public/weekend-warriors

Fave Five (10/14/2016)

expectingalpha Stocks , , , , , ,

Fave Five (10/14/2016)

Our Fave Five essentially represents a listing of stocks with favorable short term total return forecasts (1 year, according to Analyst Consensus Estimates, or ACE) combined with strong long-term return forecasts and good/excellent quality rankings.

So you’re looking at the stocks in the top 1% of all companies according to MANIFEST Rank (Return Forecast and Quality combination) that have the highest 1-year total return forecasts according to the analyst consensus estimates. (ACE)

The Fave Five This Week

  • Aaron’s Rents (AAN)
  • Celgene (CELG)
  • Cognizant Technology (CTSH)
  • Novo Nordisk (NVO)
  • Universal Display (OLED)

Context: The median 1-year return forecast (ACE) is 9.9%.

The Long and Short of This Week’s Fave Five

The Long & Short. (October 14, 2016) Projected Annual Return (PAR): Long term return forecast based on fundamental analysis and five year time horizon. Quality Ranking: Percentile ranking of composite that includes financial strength, earnings stability and relative growth & profitability. VL Low Total Return (VLLTR): Low total return forecast based on 3-5 year price targets via Value Line Investment Survey. Morningstar P/FV: Ratio of current price to fundamentally-based fair value via www.morningstar.com S&P P/FV: Current price-to-fair value ratio via Standard & Poor’s. 1-Year ACE Outlook: Total return forecast based on analyst consensus estimates for 1-year target price combined with current yield. The data is ranked (descending order) based on this criterion. 1-Year S&P Outlook: 1-year total return forecast based on S&P 1-year price target. 1-Yr GS: 1-year total return forecast based on most recent price target issued by Goldman Sachs.

Weekend Warriors

The relative/excess return for the Weekend Warrior tracking portfolio is +9.8% since inception. 44.3% of selections have outperformed the Wilshire 5000 since original selection.

Tracking Dashboard: https://www.manifestinvesting.com/dashboards/public/weekend-warriors

Novo Nordisk (NVO)

expectingalpha Stocks ,

This is a sample stock analysis, the type of feature that we regularly share with subscribers at http://www.manifestinvesting.com  Stocks selected for this monthly feature have outperformed the market (Wilshire 5000) for over 12 years.  FREE test drives and trial subscriptions available.

Solomon Select (October 2016)

Novo Nordisk (NVO)

This month we take a look at another “flavor” of repeat selections. Guest damsel Kim Butcher presented this world class leader in insulin and diabetes care during the August and September Round Table webcasts. The audience was polled and sanctioned the nomination both times.

As detailed in recent Barron’s coverage, Denmark’s Novo Nordisk (NVO), the global leader in diabetes medications, will get a new CEO in January, when company insider Lars Fruergaard Jørgensen takes the reins from his long-serving predecessor. But don’t expect the company’s strategy to change, even though increased competition and turmoil in the U.S. health-care market lately have pressured results.

NVO intends to stay the course, building on its No. 1 status in diabetes management, and expanding its drug pipeline into other lucrative areas, such as medications to fight obesity, hormone regulation and treatment of hemophilia. With a portfolio of new and more efficacious diabetes drugs, and other promising treatments in the wings, the company is likely to win back investors.

Novo Nordisk (NVO): Business Model Analysis. 9-10% top line growth has been the trend for NVO in the face of economic pressures in Europe and the long term market drivers (demographics and obesity macro trends) suggest continuing growth. Profitability has been steadily improving but will likely plateau under competitive pressures and P/E ratios in the realm of 20x seem reasonable going forward.

Growth, Profitability, Valuation

The Manifest Investing sales growth forecast for NVO is 9.2%. Value Line has a 3-5 year sales growth forecast of 10% and Morningstar “dissents” a little with 5% revenue growth expectation through 2020. The company has scaled back top line growth projections for 2016 to 5-7% and the analyst consensus expects a continuation in 2017. Novo Nordisk “should return to double-digit growth when new products reach critical mass,” says ABG Sundal Collier analyst Andrew Carlsen. But that might not happen before the end of 2018. By then, sales of new products could offset the effects of U.S. pricing pressure.

We’re using 31.0% for the projected net margin. The average net margin has been 28.2% for the period 2010-2015. Value Line has a 3-5 year projected net margin of 34.0%. The trend as shown in the accompanying profitability graphic is strong and in the right direction. Morningstar acknowledges pressures on margins but stipulates that manufacturing efficiencies and product mix will alleviate some of this.

The median P/E for the period 2008-2015 is 20.3×. We’re using 21x for the projected average P/E.

At the time of selection (10/4/2016), the stock price is $40.63, the projected annual return is 15-16%. The quality RANKING is 99 (Excellent, Top Shelf) and the financial strength rating is 94 (A+).

Points of View

The Value Line low total return forecast for NVO is approximately 12%. Morningstar has NVO with a fair value of $51 for a price-to-fair value ratio of 82%.

Last week, the company announced it would cut about 1,000 jobs from its 42,300-strong workforce to reduce costs. The move underscores Novo Nordisk’s struggle to maintain strong growth amid the competition in the insulin market, which accounts for more than half its sales. The company has a strong track record when it comes to return on research invested, comparing favorably versus Sanofi and other major pharma players. That said, the departure of the CEO and the apparent intentions to expand efforts in new insulin technologies and other frontiers could possibly mark a directional shift for the company. Value Line continues to look for expansion of the diabetes business … issue took a hit following loss of a contract with Express Scripts and lowered guidance … creating a potentially favorable entry point for patient investors.

Fave Five (10/7/2016)

expectingalpha Stocks , , , , , ,

Fave Five (10/7/2016)

Our Fave Five essentially represents a listing of stocks with favorable short term total return forecasts (1 year, according to Analyst Consensus Estimates, or ACE) combined with strong long-term return forecasts and good/excellent quality rankings.

So you’re looking at the stocks in the top 1% of all companies according to MANIFEST Rank (Return Forecast and Quality combination) that have the highest 1-year total return forecasts according to the analyst consensus estimates. (ACE)

The Fave Five This Week

  • Cognizant Technology (CTSH)
  • CVS Health (CVS)
  • Hain Celestial (HAIN)
  • Novo Nordisk (NVO)
  • Simulations Plus (SLP)

Context: The median 1-year return forecast (ACE) is 9.6%.

The Long and Short of This Week’s Fave Five

The Long & Short. (October 7, 2016) Projected Annual Return (PAR): Long term return forecast based on fundamental analysis and five year time horizon. Quality Ranking: Percentile ranking of composite that includes financial strength, earnings stability and relative growth & profitability. VL Low Total Return (VLLTR): Low total return forecast based on 3-5 year price targets via Value Line Investment Survey. Morningstar P/FV: Ratio of current price to fundamentally-based fair value via www.morningstar.com S&P P/FV: Current price-to-fair value ratio via Standard & Poor’s. 1-Year ACE Outlook: Total return forecast based on analyst consensus estimates for 1-year target price combined with current yield. The data is ranked (descending order) based on this criterion. 1-Year S&P Outlook: 1-year total return forecast based on S&P 1-year price target. 1-Yr GS: 1-year total return forecast based on most recent price target issued by Goldman Sachs.

Weekend Warriors

The relative/excess return for the Weekend Warrior tracking portfolio is +7.3% since inception. 44.1% of selections have outperformed the Wilshire 5000 since original selection.

Tracking Dashboard: https://www.manifestinvesting.com/dashboards/public/weekend-warriors

Fave Five (9/9/2016)

expectingalpha Stocks , , , , , ,

Fave Five (9/9/2016)

We took another slight detour this week to focus on some high-quality stocks with superior long term return forecasts that are near the top of our Sweet Spot. It was a great week for the Weekend Warriors highlighted over the last year as the tracking portfolio now has a rate of return of 16.9% versus 11.2% for the Wilshire 5000 since inception.

The Fave Five This Week

  • Akamai (AKAM)
  • CVS Health (CVS)
  • Novo Nordisk (NVO)
  • Redhat (RHT)
  • Ulta Salon (ULTA)

Context: The average 1-year total return forecast for the Value Line 1700 is 14.7%. The average 5-year return forecast for $VLE is 5.5% (annualized).

This Week’s Fave Five: Top Of The Sweet Spot

Top Of The Sweet Spot. (September 9, 2016) Projected Annual Return (PAR): Long term return forecast based on fundamental analysis and five year time horizon. Quality Ranking: Percentile ranking of composite that includes financial strength, earnings stability and relative growth & profitability.

Weekend Warriors

The return for the Weekend Warrior tracking portfolio is 16.9% since inception. (Wilshire 5000 is at 11.2%) 48.3% of selections have outperformed the Wilshire 5000 since original selection.

Tracking Dashboard: https://www.manifestinvesting.com/dashboards/public/weekend-warriors

Look Out Below: MYL, NVO & RHI

expectingalpha Stocks , ,

Lookout Below

During the weekly update, the following stocks were flagged based on a decline from RSI greater than 70 (potentially overbought) to less than 70. Reminder: We use a long-term chart (monthly) for this analysis.

All of these companies should be subjected to an assertive portfolio-centered selling analysis.

  • Mylan Labs (MYL)
  • Novo Nordisk (NVO)
  • Robert Half (RHI)

Lob dash 20130412

Mylan Labs (MYL)

Myl 10yr 20130412

Novo Nordisk (NVO)

Love the company … would probably want to wait for a slightly higher PAR and a clear reversal in the RSI trend.

Nvo 10yr 20130412

Robert Half (RHI)

This community favorite has had a heckuva run over the last several months. With a PAR (5.9%) less than the market average (MIPAR = 7.0%) and relatively rare RSI breaks and excursions over the last ten years, if you’re holding this high-quality (Quality Rank = 88th percentile) career and employment leader, your recent gains may be worth capturing/protecting.

Check overall portfolio return forecasts and this RSI break condition could be a tiebreaker when pondering selling candidates.

Rhi 10yr 20130412

Value Line Low Total Return Screen (1/11/2013)

expectingalpha Stocks

I first became aware of Novo Nordisk (NVO) back in 1996 when Charles Carlson mentioned it in one of his newsletters and explained his thesis at an investment conference. His thesis is still intact. The company designs and delivers medical treatments (including innovations in insulin delivery) for diabetes and a variety of other conditions (including coagulation and hormone replacement therapy.) Over the past sixteen years, Novo Nordisk has an annualized total return of 21.3% during a period when the S&P 500 delivered 4.3% — for a relative return of +17.0%! It’s nice to see Value Line give the 3-5 year forecast price a boost in this week’s update. Novo Nordisk might be something of a gold standard for a pounce pile. Buying opportunities have been limited (current conditions aren’t quite there yet) but they’re worth waiting for. We’ll be waiting, watching and willing to accumulate when that time comes.

Materially Stronger: Mylan Labs (MYL), Novo Nordisk (NVO)

Materially Weaker: DuPont (DD), AstraZeneca (AZN), Kelly Services (KELYA), Pan American Silver (PAAS)